Repotrectinib TPX 0005 is a rationally designed, low-molecular-weight, macrocyclic TKI that is selective and highly potent against ROS1, TRKA–C, and ALK. Most importantly, repotrectinib exhibits activity against a variety of solvent-front substitutions in vitro and in vivo. Repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion–positive cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) have a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share which is quite hight. BMS has seen the big potential of Repotrectinib, so as Jinan Million Pharm. We already r & D and make it commercial production. Once FDA approved it, Jinan Million will have stock of tpx 0005 api powder in stock and ready shipment. We will be the first manufacturer and factory of Repotrectinib.
Why Choose Us ？
1 、 Manufacturer supply, best price and service.
2、 Safe fast delivery.
3、 F ree sample.
4、 Large stock.
5、 Easy payment: bank transfer, moneygram, paypal....
6、 Good reputation, great feedback.
7、 Customers worldwide: Metrochem Api Pvt Ltd;Bdr Lifesciences Pvt.Ltd;Srini Chem;Eva Pharma;Pharmaffiliates Analytics&Synthetics(p)Ltd;....From India,Egypt,Canada ....
-Packing&Shipping-
About us:
Founded in 2012, Jinan Million Pharmaceutical Co., Ltd (Jinan Milin Pharmaceutical Co., Ltd) is a modern pharmaceutical enterprise guided by innovation. Million pharm has excellent research and development capabilities and complete industrial bases with international quality management system. It is dedicated to the research, development, production and customization of pharmaceuticals and advanced pharmaceutical intermediates.
Jinan Million Pharmaceutical Co., Ltd has been focusing on the research of Cerebro-cardiovascular drugs, Central nervous system drugs, Anti-cancer drugs, Antibacterial drugs and others for 12 years; the products are: Apixab a n, Lurasidon e , Bexagliflozin, Vortioxetine, L OXO -292/Selpercatinib, Baricitinib and intermediates. Million has worked with reputable customers, like METROCHEM API PVT LTD; BDR LIFESCIENCES PVT.LTD; SRINI CHEM; EVA PHARMA; PHARMAFFILIATES ANALYTICS & SYNTHETICS (P) LTD; ....from India, Egypt, Canada...
Jinan Million Pharmaceutical Co., Ltd has a 1,500㎡ R&D center in the Zhongguancun E Valley (Qihe) Incubator, equipped with complete test equipment, such as high-performance liquid chromatography, nuclear magnetic resonance spectrometer, liquid chromatography mass spectrometer, automatic polarimeter, etc., which can meet the needs of various laboratory scale tests in different conditions. The pilot workshop is equipped with 50L and 100L glass reactors, high and low temperature equipment, etc., which can support organic chemical reactions at -100°C or 200°C. In addition, Million has a production site in Linyi city with many independent production lines, such as: production line of Apixabn intermediate 20 tons/year, production line of Lurasidon intermediate 10 tons/year, which can meet the commercial production of various products.
The technical team is composed of high-level talents in major of pharmacy, bio-pharmaceutical or chemical synthesis, of which 10% has doctor’s degree and 15% has master’s degree. The team members are young and energetic with innovative spirit and willing to overcome obstacles.
Jinan Million Pharmaceutical Co., Ltd adheres to the business philosophy of "dedication and innovation", insists on pioneering and innovating, constantly improves the quality system, and vigorously trains technical and management talents to build an elite team and serves customers better. Looking forward to cooperate with you for joint development and common progress.
